December 21, 2023
3 min watch
Save
VIDEO: Ruxolitinib plus pelabresib shows promise in MANIFEST-2 study
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, John Mascarenhas, MD, discussed the MANIFEST-2 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.
Mascarenhas, professor of medicine at the Icahn School of Medicine at Mount Sinai, discussed the study, which examined a combination of ruxolitinib plus pelabresib into intermediate and high-risk myelofibrosis, which provided results that Mascarenhas called “encouraging.”
“I think that there's still a path forward for this drug in combination with ruxolitinib in JAK inhibitor-naïve patients, and the totality of the data suggests a benefit there,” Mascarenhas said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio interview
Disclosures:
Mascarenhas reports numerous ties to industry.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.